Immune checkpoint blockade (ICB) therapy employs ICIs to target and block CTLA-4 and/or PD-1 receptors on immune cells or their ligands—CD80/CD86 and PD-L1—on tumor cells to enhance T cell activation and antigen-specific response [95]. This evidence concerns the gene CTLA4 and neoplasm.